Estimation of the risk of secondary malignancy arising from whole-breast irradiation: Comparison of five radiotherapy modalities, including TomoHDA

Eun Young Han, Nava Paudel, Jiwon Sung, Myonggeun Yoon, Weon Kuu Chung, Dong Wook Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)


The risk of secondary cancer from radiation treatment remains a concern for long-term breast cancer survivors, especially those treated with radiation at the age younger than 45 years. Treatment modalities optimally maximize the dose delivery to the tumor while minimizing radiation doses to neighboring organs, which can lead to secondary cancers. A new TomoTherapy treatment machine, TomoHDATM, can treat an entire breast with two static but intensity-modulated beams in a slice-by-slice fashion. This feature could reduce scattered and leakage radiation doses. We compared the plan quality and lifetime attributable risk (LAR) of a second malignancy among five treatment modalities: three-dimensional conformal radiation therapy, field-in-field forward-planned intensity-modulated radiation therapy, inverse-planned intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy, and TomoDirect mode on the TomoHDA system. Ten breast cancer patients were selected for retrospective analysis. Organ equivalent doses, plan characteristics, and LARs were compared. Out-of-field organ doses were measured with radio-photoluminescence glass dosimeters. Although the IMRT plan provided overall better plan quality, including the lowest probability of pneumonitis, it caused the second highest LAR. The TomoTherapy plan provided plan quality comparable to the IMRT plan and posed the lowest total LAR to neighboring organs. Therefore, it can be a better treatment modality for younger patients who have a longer life expectancy.

Original languageEnglish
Pages (from-to)22960-22969
Number of pages10
Issue number16
Publication statusPublished - 2016 Apr 19



  • Breast
  • IMRT
  • Secondary malignancy
  • TomoHDA
  • VMAT

ASJC Scopus subject areas

  • Oncology

Cite this